Research Alliance Corp III

EX-99.1 8 d149484dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Scalar, LLC (“Scalar”), hereby consents to (i) the filing of our fairness opinion dated August 24, 2026 (the “Opinion”) to the Board of Directors of Research Alliance Corporation III (“RACC”) as Annex L to the proxy statement/prospectus contained in this Registration Statement on Form S-4, (ii) the references therein to Scalar and (iii) the inclusion therein of (a) the summaries of and excerpts from the Opinion, (b) the description o…

S-4 · 2026-08-24 · 0001193125-26-363800

EX-99.1 9 d101725dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance Corporation III’s (Nasdaq: RACC) (“RACC”) trust account that is …

8-K · 2026-07-27 · 0001193125-26-316954

EX-99.2 10 d101725dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Oak Hill Bio Investor Presentation July 2026 Private and Confidential - Not to be Retained CORPORATE Disclaimers (1 of 3) This presentation (together with oral statements made in connection herewith this “Presentation”) is provided for informational purposes only. This Presentation has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between OHB Pediatrics Ltd…

8-K · 2026-07-27 · 0001193125-26-316954

Exhibit 99.1 INDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of Research Alliance Corporation III: Report of Independent Registered Public Accounting Firm (PCAOB #199) F-2 Balance Sheet as of May 21, 2026 F-3 Notes to Financial Statement F-4 Report of Independent Registered Pub…

8-K · 2026-05-28 · 0001193125-26-245567

Exhibit 99.1 RESEARCH ALLIANCE CORPORATION III ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING NEW YORK, May 19, 2026 - Research Alliance Corporation III (the “Company”), a special purpose acquisition company, announced today the pricing of its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share. The shares will be listed on the Nasdaq Capital Market and trade under the ticker symbol “RACC” beginning May 20, 2026. The Company expects the offering to close…

8-K · 2026-05-21 · 0001193125-26-234382

EX-99.1 12 d43164dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONSENT OF MICHAEL F. MACLEAN Research Alliance Corporation III intends to file an Amendment No. 2 to the Registration Statement on Form S-l (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration Statem…

S-1/A · 2026-05-13 · 0001193125-26-220331